Search

Your search keyword '"Yoshitaka, Narita"' showing total 255 results

Search Constraints

Start Over You searched for: "Yoshitaka, Narita" Remove constraint "Yoshitaka, Narita" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
255 results on '"Yoshitaka, Narita"'

Search Results

51. Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas.

53. Male sex and presence of preoperative symptoms are associated with early recurrence of WHO grade I meningiomas after surgical resection: analysis from the nationwide Brain Tumor Registry of Japan.

56. Prognostic factors associated with the transition in treatment methods for brain metastases from colorectal cancer.

57. Assessing the reporting quality of adult neuro-oncology protocols, abstracts, and trials: Adherence to the SPIRIT and CONSORT statements.

58. Reviewers.

62. A retrospective analysis of the prognosis of Japanese patients with sarcoma brain metastasis.

63. High-grade neuroepithelial tumor with EP300::BCOR fusion and negative BCOR immunohistochemical expression: a case report.

64. Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma.

65. Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.

66. Prediction of tissue-of-origin of early stage cancers using serum miRNomes.

68. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.

69. Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence.

70. Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases.

72. Male sex and presence of preoperative symptoms are associated with early recurrence of WHO grade I meningiomas after surgical resection: analysis from the nationwide Brain Tumor Registry of Japan.

74. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.

75. Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas.

76. Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.

77. Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma.

81. Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy.

82. Clinical application of a highly sensitive digital PCR assay to detect a small fraction of IDH1 R132H-mutant alleles in diffuse gliomas.

83. Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies.

84. Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient's IADL?

85. Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts.

88. Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas.

89. Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma.

90. MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas.

91. Surgical site infection caused by Rhizopus caespitosus after metastasectomy for osteosarcoma: First report of infection in humans.

92. The clinical characteristics and outcomes of incidentally discovered glioblastoma.

93. Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.

94. Reviewers.

97. Differences in the approaches of cancer specialists toward adolescent and young adult cancer care.

100. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.

Catalog

Books, media, physical & digital resources